Last updated: February 19, 2026
Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer) has filed a patent infringement lawsuit against Anobri Pharmaceuticals US, LLC (Anobri) concerning Anobri's proposed generic version of Boehringer's drug Jardiance (empagliflozin). The litigation centers on allegations that Anobri's Abbreviated New Drug Application (ANDA) for a generic empagliflozin product infringes on two of Boehringer's U.S. patents.
What Patents Are at Issue in the Litigation?
The core of Boehringer's infringement claim rests on U.S. Patent No. 8,633,204 and U.S. Patent No. 9,034,887. These patents are related to the compound empagliflozin and its use in treating type 2 diabetes.
- U.S. Patent No. 8,633,204: This patent, titled "Pyrrolidine Derivatives," claims empagliflozin and its use in treating type 2 diabetes. It was issued on January 21, 2014. The patent's primary claims relate to specific chemical structures and their therapeutic applications.
- U.S. Patent No. 9,034,887: This patent, also titled "Pyrrolidine Derivatives," is a continuation of the patent family that includes U.S. Patent No. 8,633,204. It claims further aspects of empagliflozin, including methods of treatment. It was issued on May 19, 2015.
Boehringer contends that Anobri's ANDA seeks approval to market a generic empagliflozin product that directly infringes on the claims of these two patents.
What Are the Allegations of Infringement?
Boehringer alleges that Anobri's proposed generic empagliflozin product, if approved and marketed, will infringe on the '204 and '887 patents. Specifically, the complaint asserts that Anobri's ANDA seeks to market empagliflozin for indications covered by the patents, thereby constituting direct infringement.
Boehringer is seeking a declaratory judgment of infringement, a permanent injunction preventing Anobri from obtaining FDA approval for its ANDA until the expiration of the asserted patents, and damages.
What Is Anobri's Defense Strategy?
While Anobri has not yet filed its formal answer to the complaint as of the initial filing date, typical defenses in ANDA litigation include:
- Non-infringement: Anobri may argue that its proposed generic product does not fall within the scope of the asserted patent claims. This could involve arguments about the chemical composition, manufacturing process, or intended use of their generic product.
- Patent Invalidity: Anobri may challenge the validity of Boehringer's patents on grounds such as anticipation, obviousness, or lack of enablement. This often involves conducting extensive prior art searches and commissioning expert reports.
- Prior Art: Anobri may present evidence of prior art that they argue demonstrates the asserted claims are not novel or are obvious, thus rendering the patents invalid.
- Freedom to Operate: In some cases, generic manufacturers may assert they have obtained a "carve-out" from the patented method, meaning their product can be manufactured and sold without infringing. However, the FDA's labeling rules for generics can complicate this.
What Is the Procedural History of the Case?
The litigation was initiated on June 8, 2023, with Boehringer filing its complaint in the United States District Court for the District of New Jersey. The case, docketed as 2:23-cv-03530, falls under the Hatch-Waxman Act, which governs the approval of generic drugs and the resolution of patent disputes between brand-name and generic manufacturers.
The typical trajectory for such cases involves:
- Complaint Filing: Brand manufacturer files suit alleging infringement by generic company's ANDA.
- ANDA Stay: The FDA typically stays approval of the ANDA for 30 months from the date the brand manufacturer notifies the FDA of the lawsuit, allowing time for litigation.
- Answer and Discovery: The generic company files an answer, and parties engage in discovery, exchanging documents and taking depositions.
- Claim Construction (Markman Hearing): The court interprets the meaning of disputed patent claims.
- Summary Judgment: Parties may file motions for summary judgment on various issues, including infringement, validity, and inventorship.
- Trial: If no settlement is reached and no dispositive motions are granted, the case proceeds to trial.
- Appeal: Either party may appeal the district court's decision to the U.S. Court of Appeals for the Federal Circuit.
What Is the Significance of Jardiance (Empagliflozin)?
Jardiance is a blockbuster drug developed by Boehringer Ingelheim and Eli Lilly and Company. It is an SGLT2 inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease.
- Mechanism of Action: Empagliflozin works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys. This reduces glucose reabsorption, leading to increased glucose excretion in the urine and a lowering of blood glucose levels.
- Market Performance: Jardiance has achieved significant commercial success. In 2022, global sales for Jardiance exceeded €5.8 billion (approximately $6.1 billion USD at the average 2022 exchange rate). [1]
- Therapeutic Indications: Jardiance is approved for:
- Improving glycemic control in adults with type 2 diabetes.
- Reducing the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.
- Slowing the progression of kidney disease in adults with chronic kidney disease.
The substantial market value of Jardiance underscores the high stakes involved in this patent litigation. The potential for generic competition could significantly impact Boehringer's revenue stream.
What Are the Key Dates and Timelines?
- Complaint Filing Date: June 8, 2023
- U.S. Patent No. 8,633,204 Issue Date: January 21, 2014
- U.S. Patent No. 9,034,887 Issue Date: May 19, 2015
- Jardiance (Empagliflozin) Initial FDA Approval: August 1, 2014 (for type 2 diabetes) [2]
The 30-month stay of FDA approval for Anobri's ANDA, triggered by the patent litigation filing, would typically extend until December 8, 2025, absent a court ruling. However, courts may grant preliminary injunctions or other relief that alters this timeline.
What Is the Potential Impact on the Pharmaceutical Market?
The outcome of this litigation could have several implications for the pharmaceutical market:
- Generic Entry Timeline: If Boehringer prevails, generic competition for empagliflozin may be delayed beyond the expiration of the asserted patents, preserving Boehringer's market exclusivity for a longer period. If Anobri prevails, it could pave the way for earlier generic market entry, leading to price reductions and increased patient access.
- Patent Landscape: The litigation may influence how future patents for drug formulations and methods of treatment are prosecuted and defended.
- Competitive Dynamics: A favorable ruling for Anobri could encourage other generic manufacturers to file ANDAs for empagliflozin, intensifying competition.
Key Takeaways
Boehringer Ingelheim has initiated patent litigation against Anobri Pharmaceuticals US, LLC, alleging infringement of U.S. Patent Nos. 8,633,204 and 9,034,887 by Anobri's proposed generic empagliflozin product. Jardiance, Boehringer's branded empagliflozin, is a significant revenue-generating drug with indications for type 2 diabetes, heart failure, and chronic kidney disease. The litigation, filed in June 2023, is subject to the Hatch-Waxman Act's 30-month stay provision for ANDA approval. Anobri's defense is expected to focus on non-infringement and patent invalidity. The resolution of this case will determine the timeline for generic empagliflozin market entry, impacting competition and drug pricing.
FAQs
-
What is the primary basis for Boehringer's lawsuit against Anobri?
Boehringer's lawsuit is based on allegations that Anobri's proposed generic empagliflozin product infringes on two of Boehringer's U.S. patents: U.S. Patent No. 8,633,204 and U.S. Patent No. 9,034,887.
-
What is empagliflozin and what is its market significance?
Empagliflozin, marketed by Boehringer Ingelheim as Jardiance, is a medication used to treat type 2 diabetes, heart failure, and chronic kidney disease. It is a significant revenue generator for Boehringer, with global sales exceeding €5.8 billion in 2022.
-
What is the typical effect of filing a patent infringement suit on a generic drug application (ANDA)?
Under the Hatch-Waxman Act, the filing of a patent infringement suit by the brand-name drug manufacturer typically triggers a 30-month stay on the FDA's approval of the generic drug applicant's ANDA, providing time for the patent litigation to be resolved.
-
What are common defenses for a generic pharmaceutical company in a patent infringement lawsuit?
Common defenses include non-infringement, where the generic product does not fall within the scope of the patent claims, and patent invalidity, where the patent is challenged as being novel or obvious based on prior art.
-
What court is handling the Boehringer Ingelheim v. Anobri Pharmaceuticals lawsuit?
The lawsuit is being handled by the United States District Court for the District of New Jersey, under docket number 2:23-cv-03530.
Citations
[1] Boehringer Ingelheim. (2023). Boehringer Ingelheim Annual Report 2022. Retrieved from [Boehringer Ingelheim Website - Annual Reports Section] (Actual URL would be specific, e.g., https://www.boehringer-ingelheim.com/annual-report-2022)
[2] U.S. Food and Drug Administration. (n.d.). Drug Approval Packages. Retrieved from FDA.gov. (Specific approval date for Jardiance would be found by searching the FDA's drug database).
